117. 脊髄空洞症
[臨床試験数:2,薬物数:4(DrugBank:0),標的遺伝子数:0,標的パスウェイ数:0]

Searched query = "Syringomyelia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02807142
(ClinicalTrials.gov)
March 20163/6/2016Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic SyringomyeliaEfficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic SyringomyeliaPost-Traumatic SyringomyeliaBiological: NC 1 cell therapyPuerta de Hierro University HospitalNULLCompleted18 Years70 YearsAll6Phase 2NULL
2EUCTR2015-002383-16-ES
(EUCTR)
19/01/201615/10/2015Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyeliaEvaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyelia Traumatic spinal cord injury, chronically established, associated with syringomyelia and neurological deficit considered irreversible.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Células mesenquimales troncales adultas autólogas de medula ósea expandidas
Product Code: CME-LEM4
INN or Proposed INN: células mesenquimales troncales adultas autólogas de médula ósea expandidas
Fundación Investigación Biomédica Hospital Universitario Puerta de HierroNULLNot RecruitingFemale: yes
Male: yes
6Phase 2Spain